HERConnection
a support program made for you
What you need, when you need it—information and resources to help you stay on track and stay on top of your HER2+ breast cancer treatment journey.
What you need, when you need it—information and resources to help you stay on track and stay on top of your HER2+ breast cancer treatment journey.
What you need, when you need it—information and resources to help you stay on track and stay on top of your HER2+ breast cancer treatment journey.
HERConnection is a free support program designed specifically for people with HER2+ breast cancer taking Genentech medicines, providing information and resources that can help educate and empower you throughout your treatment journey.
Remember, your doctor and your healthcare team are your primary sources of information. Only they can give you medical advice about your disease and treatment.
Keep track of your appointments and notes
Help with hydration during treatment
Cookbook made specifically for patients and caregivers
Facts about the medicine you are taking and what to expect during treatment
Tips for healthy eating, staying active, and emotional well-being during and after treatment
Detailed guidance around financial assistance options you may be eligible for
Connect with various support groups and resources that you can tap into
*Be aware that materials and information may differ depending on your course of treatment.
When you sign up, you will receive emails and packages in the mail over the course of your treatment journey.
Since everyone’s journey is a little different, we do our best to deliver only the materials and information that make the most sense for you depending on your course of treatment.
![]() |
Thank you for signing up for HERConnection. We’ve received your information and look forward to connecting with you. Stay tuned and keep an eye on your inbox—support for your treatment journey is on its way! |
Remember, your doctor and your healthcare team should be your primary source of information. Only they can give you medical advice about your disease and treatment. Genentech’s intent is to provide information only to patients and caregivers in the United States or its territories.
By providing your information, you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents in the future regarding Genentech Products and related disease education. Furthermore, you are agreeing that Genentech and its agents may contact you by phone, email, or mail, and that such electronic or other written communications may include information regarding your health within them. Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with the Genentech Privacy Policy.
If you have any questions about the Genentech Privacy Policy or the information practices of our sites, you may contact us
by e-mail at [email protected]
or by mail at:
Genentech, Inc.
Attn: Privacy Office
1 DNA Way
South San Francisco, CA 94080
The Genentech Patient Resource Center can help answer questions and connect you to an appropriate Genentech patient support service.
1 (877) GENENTECH (436-3683) | Monday-Friday, 6am-5pm PST
This is not meant to replace the advice of your healthcare team.
HERConnection is designed specifically for people with HER2+ breast cancer who are taking Genentech medicines. That means you can sign up if you’re currently taking PERJETA + Herceptin-based therapy, KADCYLA, or PHESGO for HER2+ breast cancer.
If you are a caregiver to someone taking one of these medicines, you are welcome to sign up on their behalf, but keep in mind that you will be receiving information and resources geared toward your loved one.
Unfortunately, HERConnection is only available to people who are taking Genentech medicines like PERJETA + Herceptin-based therapy, KADCYLA, or PHESGO.
If you have HER2+ breast cancer, you can talk to your healthcare team about your treatment options and if one of these medicines might be right for you.
When you sign up, you’ll receive a number of emails over the course of your treatment journey. Each email will contain information, tips, and guidance relevant to that particular stage in your breast cancer treatment experience.
You’ll also receive one or more packages in the mail with more helpful information, as well as free tools that you can use to support a healthy lifestyle. These may include a treatment journal, water bottle, and cookbook designed specifically for cancer patients and caregivers.
Remember that everyone’s journey is a little different. So it’s important that you tell us a bit about your treatment plan so we can deliver the materials and information that make the most sense for you.
Absolutely not! HERConnection is 100% free. If you have HER2+ breast cancer and are taking a Genentech medicine, you are eligible to sign up for free to get information and resources to help guide you throughout your treatment journey.
HERConnection does not provide financial assistance.
However, there are a number of other resources that Genentech offers to help you afford your medicine, no matter what type of health insurance you have.
You can explore financial resources here or call the Genentech Patient Resource Center at (877) GENENTECH/(877) 436-3683 to learn more.
Of course you can! But it’s helpful to fill in a start date. The more information you give us, the better we can guide and support you. We are committed to delivering information, tips, and resources that are timely and that align with your treatment experience, when you need it.
If you’re not sure of your start date, you can ask your healthcare team, or make a rough guess.
Yes. It’s easy to opt out. Just click on the “Unsubscribe” button in any of the emails you receive. Or you can call the Genentech Patient Resource Center at (877) GENENTECH/(877) 436-3683.
Your personal information is only being collected so we can provide you with relevant information and resources based on your treatment journey.
By providing your information, you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents in the future regarding Genentech Products and related disease education. Furthermore, you are agreeing that Genentech and its agents may contact you by phone, email, or mail, and that such electronic or other written communications may include information regarding your health within them.
Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with the Genentech Privacy Policy.
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.
The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen before surgery are:
Side effects may vary based on chemotherapy regimen.
The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are:
The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Early Breast Cancer
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.
Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Metastatic Breast Cancer
KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Liver problems
Heart problems
Pregnancy
Contact your doctor right away if you experience symptoms associated with these side effects.
Lung problems
Infusion-related reactions
Serious bleeding
Low platelet count
Nerve damage
Skin reactions around the infusion site
The most common side effects in people taking KADCYLA for early breast cancer are:
The most common side effects seen in people taking KADCYLA for metastatic breast cancer are:
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.
Please see full Prescribing Information for Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
PHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
PHESGO may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
Receiving PHESGO during pregnancy can result in the death of an unborn baby and birth defects.
PHESGO may cause serious lung problems.
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
The most common side effects of PHESGO when given with docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Thank you for your interest.
The HERConnection support program is only available to people receiving treatment with a Genentech medication.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.